Kalaris Therapeutics, Inc. announced a private placement agreement with institutional accredited investors, raising $50.0 million. The placement includes 4,200,000 shares of common stock at $10.00 per share and warrants to purchase 800,000 shares at $9.9999 each. The proceeds will fund operations until Q3 2027, advancing the clinical development of TH103 for neovascular AMD. Morgan Stanley and Leerink Partners are lead placement agents. The securities have not been registered and will be resold under a registration statement. Kalaris Therapeutics, founded by Dr. Napoleone Ferrara, is focused on treatments for retinal diseases with unmet medical needs.

Read more at GlobeNewswire: Kalaris Therapeutics Announces Oversubscribed $50.0 Million